🚀 VC round data is live in beta, check it out!
Amoytop Biotech Valuation Multiples
Discover revenue and EBITDA valuation multiples for Amoytop Biotech and similar public comparables like Zelgen Biopharmaceuticals, Legend Biotech, Hikma Pharmaceuticals, Tango Therapeutics and more.
Amoytop Biotech Overview
About Amoytop Biotech
Xiamen Amoytop Biotech Co Ltd operates as a drug development company. The Company develops and sells protein drugs, interferon drugs, and other products.
Founded
1996
HQ
Employees
N/A
Website
Sectors
Financials (LTM)
EV
$4B
Amoytop Biotech Financials
Amoytop Biotech reported last 12-month revenue of $578M.
In the same LTM period, Amoytop Biotech generated $536M in gross profit and $161M in net income.
Revenue (LTM)
Amoytop Biotech P&L
In the most recent fiscal year, Amoytop Biotech reported revenue of $542M and EBITDA of $191M.
Amoytop Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $578M | XXX | $542M | XXX | XXX | XXX |
| Gross Profit | $536M | XXX | $504M | XXX | XXX | XXX |
| Gross Margin | 93% | XXX | 93% | XXX | XXX | XXX |
| EBITDA | — | XXX | $191M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 35% | XXX | XXX | XXX |
| EBIT Margin | 33% | XXX | 34% | XXX | XXX | XXX |
| Net Profit | $161M | XXX | $151M | XXX | XXX | XXX |
| Net Margin | 28% | XXX | 28% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Amoytop Biotech Stock Performance
Amoytop Biotech has current market cap of $4B, and enterprise value of $4B.
Market Cap Evolution
Amoytop Biotech's stock price is $9.47.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4B | $4B | -0.7% | XXX | XXX | XXX | $0.37 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAmoytop Biotech Valuation Multiples
Amoytop Biotech trades at 6.5x EV/Revenue multiple, and 19.6x EV/EBITDA.
EV / Revenue (LTM)
Amoytop Biotech Financial Valuation Multiples
As of April 18, 2026, Amoytop Biotech has market cap of $4B and EV of $4B.
Equity research analysts estimate Amoytop Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Amoytop Biotech has a P/E ratio of 24.0x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV/Revenue | 6.5x | XXX | 6.9x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 19.6x | XXX | XXX | XXX |
| EV/EBIT | 19.4x | XXX | 20.6x | XXX | XXX | XXX |
| EV/Gross Profit | 7.0x | XXX | 7.4x | XXX | XXX | XXX |
| P/E | 24.0x | XXX | 25.6x | XXX | XXX | XXX |
| EV/FCF | 30.0x | XXX | 36.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Amoytop Biotech Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Amoytop Biotech Margins & Growth Rates
Amoytop Biotech's revenue in the last 12 month grew by 26%.
Amoytop Biotech Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 26% | XXX | 25% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 35% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 29% | XXX | XXX | XXX |
| S&M Expenses to Revenue | 39% | XXX | 39% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 13% | XXX | 12% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 11% | XXX | 10% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 59% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Amoytop Biotech Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Amoytop Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Zelgen Biopharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Legend Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Hikma Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Tango Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| ACADIA Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Amoytop Biotech M&A Activity
Amoytop Biotech acquired XXX companies to date.
Last acquisition by Amoytop Biotech was on XXXXXXXX, XXXXX. Amoytop Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Amoytop Biotech
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAmoytop Biotech Investment Activity
Amoytop Biotech invested in XXX companies to date.
Amoytop Biotech made its latest investment on XXXXXXXX, XXXXX. Amoytop Biotech invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Amoytop Biotech
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Amoytop Biotech
| When was Amoytop Biotech founded? | Amoytop Biotech was founded in 1996. |
| Where is Amoytop Biotech headquartered? | Amoytop Biotech is headquartered in China. |
| Is Amoytop Biotech publicly listed? | Yes, Amoytop Biotech is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Amoytop Biotech? | Amoytop Biotech trades under 688278 ticker. |
| When did Amoytop Biotech go public? | Amoytop Biotech went public in 2020. |
| Who are competitors of Amoytop Biotech? | Amoytop Biotech main competitors are Zelgen Biopharmaceuticals, Legend Biotech, Hikma Pharmaceuticals, Tango Therapeutics. |
| What is the current market cap of Amoytop Biotech? | Amoytop Biotech's current market cap is $4B. |
| What is the current revenue of Amoytop Biotech? | Amoytop Biotech's last 12 months revenue is $578M. |
| What is the current revenue growth of Amoytop Biotech? | Amoytop Biotech revenue growth (NTM/LTM) is 26%. |
| What is the current EV/Revenue multiple of Amoytop Biotech? | Current revenue multiple of Amoytop Biotech is 6.5x. |
| Is Amoytop Biotech profitable? | Yes, Amoytop Biotech is net-income-positive (as of the last 12 months). |
| What is the current net income of Amoytop Biotech? | Amoytop Biotech's last 12 months net income is $161M. |
| What is the current FCF of Amoytop Biotech? | Amoytop Biotech's last 12 months FCF is $125M. |
| What is Amoytop Biotech's FCF margin? | Amoytop Biotech's last 12 months FCF margin is 22%. |
| What is the current EV/FCF multiple of Amoytop Biotech? | Current FCF multiple of Amoytop Biotech is 30.0x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.